Amgen Inc. $AMGN Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,115,268 shares of the medical research company’s stock after acquiring an additional 105,183 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amgen were worth $314,729,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Angeles Wealth Management LLC increased its stake in shares of Amgen by 29.2% during the second quarter. Angeles Wealth Management LLC now owns 1,314 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 297 shares during the period. Stratos Wealth Partners LTD. raised its holdings in Amgen by 11.4% during the second quarter. Stratos Wealth Partners LTD. now owns 28,245 shares of the medical research company’s stock worth $7,886,000 after purchasing an additional 2,899 shares in the last quarter. Finally, Nicholson Wealth Management Group LLC lifted its position in Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.8%

NASDAQ AMGN opened at $369.19 on Friday. The firm’s 50 day moving average price is $337.47 and its two-hundred day moving average price is $313.68. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12. The stock has a market cap of $198.80 billion, a price-to-earnings ratio of 25.94, a PEG ratio of 3.78 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 66.90%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.76% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lifted their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Royal Bank Of Canada upped their price target on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Argus increased their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $354.04.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.